Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trump's Rx Importation Plan: Sound and Fury, Signifying Something

Executive Summary

Proposal is more of a plan to make a plan, but Pharma should realize that time is running out on its existing policy strategies.

You may also be interested in...



Playing The Trump Card On Rx Pricing

Obamacare repeal has been replaced by rebrand as Trump administration plans to use ACA’s Medicare demonstration powers to send discount cards to seniors, one of a slew of health care announcements that include Rx importation, pre-existing conditions, insulin and EpiPens.

Can’t Let Go: HHS Seeks To Overturn US Court Decision Striking Down DTC Ad Rule

The appeal is in keeping with the President Trump’s plan to stay active on drug pricing initiatives so he can claim victory on a key campaign promise.

Trump’s Maximum Pressure Campaign On US Drug Pricing

President Trump isn’t going to let the Democrats own the drug pricing debate heading into the 2020 elections, so biopharma companies can look forward to many more headlines like the importation announcement on 31 July. When will it end?

Topics

UsernamePublicRestriction

Register

PS140606

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel